Development of induced pluripotent stem cell (iPSC) technology has enabled generation of disease-specific pluripotent stem cells from the patient. 1 A typical method uses virus-mediated transfer of defined factors into fibroblastic cells 2-4 or marrow-derived mesenchymal cells. 1, 5 Some other tissues are also reported as sources for iPSC generation, including murine hepatocytes and gastric epithelial cells, 6 human keratinocytes, 7 and very recently, human blood. 8 As the variability of cellular sources becomes greater, it is attractive to address an interesting question: is each iPSC clone derived from distinct sources unique in its characteristics? Although definitive proof of iPSC cellular origin requires genetic markers, as most somatic cells (except mature lymphocytes) lack such markers, no formal data have shown reprogramming of hematopoietic cells, aside from one study that used immunoglobulin genes as markers. 9 Here, we demonstrate definitive proof for a direct reprogramming to pluripotency of primary marrow hematopoietic cells with no gene rearrangement.
Introduction
Development of induced pluripotent stem cell (iPSC) technology has enabled generation of disease-specific pluripotent stem cells from the patient. 1 A typical method uses virus-mediated transfer of defined factors into fibroblastic cells [2] [3] [4] or marrow-derived mesenchymal cells. 1, 5 Some other tissues are also reported as sources for iPSC generation, including murine hepatocytes and gastric epithelial cells, 6 human keratinocytes, 7 and very recently, human blood. 8 As the variability of cellular sources becomes greater, it is attractive to address an interesting question: is each iPSC clone derived from distinct sources unique in its characteristics? Although definitive proof of iPSC cellular origin requires genetic markers, as most somatic cells (except mature lymphocytes) lack such markers, no formal data have shown reprogramming of hematopoietic cells, aside from one study that used immunoglobulin genes as markers. 9 Here, we demonstrate definitive proof for a direct reprogramming to pluripotency of primary marrow hematopoietic cells with no gene rearrangement.
Methods

Mice
Animal experiments were performed with approval of the Institutional Animal Care and Use Committee of the Institute of Medical Science, University of Tokyo.
Generation of iPSCs from murine bone marrow progenitor cells
Lineage marker-negative (Lin Ϫ ) c-Kit ϩ (Kit ϩ ) cells were enriched using immunomagnetic beads. pMXs vectors 10 encoding iPSC genes are described. 1 Concentrated vesicular stomatitis virus-G-retroviral supernatant was prepared using reported procedures. [11] [12] [13] 293GP and 293GPG cells were kind gifts from Dr R. C. Mulligan (Children's Hospital Boston, Harvard Medical School, Boston, MA). 14 Detailed procedures are described in the text and supplemental data (available on the Blood website; see the Supplemental Materials link at the top of the online article).
In vitro and in vivo assessment of iPSCs
Characteristics of iPSCs were assessed following reported procedures. 1 Primer sequences are shown in supplemental Table 1 . Immunoglobulin heavy chain gene rearrangement was analyzed following described methods. 15, 16 A single-base difference within Cd45 exon 25 was analyzed as reported. 17 
Results and discussion
To prove the cellular origin of iPSC clones formally, use of definitive genetic markers is necessary, as with reported reprogramming of mature B cells 9 and pancreatic beta cells. 18 Even if iPSCs are generated from hematopoietic stem/progenitor cells (HSPCs), nearly 100% positive for the hematopoietic marker CD45, one might argue, in light of reported generation of iPSCs from marrow stromal cells, 1, 5 that a small number of nonhematopoietic cells had been reprogrammed. However, no such suitable marker exists for hematopoietic cells (excepting rearranged immunoreceptor genes in mature lymphocytes). We therefore exploited a prominent characteristic of the hematopoietic system: transplantation of a single hematopoietic stem cell (HSC) can reconstitute host hematopoiesis. 19 Figure 1A depicts our experimental design. We attempted iPSC generation from marrow HSPCs harvested long-term (ϳ 10 months) after reconstitution from a single HSC of C57BL6 (B6) Ly 5.1 origin. We used concentrated vesicular stomatitis virus-G-pseudotyped retroviruses, 14 as we had succeeded in their efficient transduction into murine HSPCs. 12, 13 We purified from bone marrow (BM) of a reconstituted mouse (B6 Ly5.2) Lin Ϫ Kit ϩ cells, a HSPC population, with approximately 98% of cells expressing CD45 ( Figure 1B ). We then transduced these cells with a cocktail of retroviral vectors harboring each of the iPSC factor genes Oct4, Sox2, Klf4, and c-Myc, transferred onto mouse embryonic fibroblast cells, and maintained in the presence of leukemia inhibitory factor until cell sorting ( Figure 1B) . Visible iPSC-like colonies appeared on approximately days 9 to 11 among a majority of hematopoietic cells that remained nonreprogrammed; these colonies then grew steadily (supplemental Figure 1A) . To enrich iPSC candidates, we sorted the cells expressing SSEA-1 on approximately days 14 to 16 and allowed them to regrow for another 7 to 12 days ( Figure 1B) . Generated iPSC-like colonies showing typical embryonic stem (ES) cell-like appearance were picked up on approximately days 21 to 28. These cells showed robust stability in phenotype, had high alkaline phosphatase (ALP) activity ( Figure 1C) , and expressed SSEA-1 at levels comparable with those in ES cells (supplemental Figure 1B) . In the absence of leukemia inhibitory factor, they readily formed embryoid bodies (data not shown). By using a single-base polymorphism in CD45, 17 we could demonstrate that, of the iPSC clones thus established, 3 were derived from Ly5.1 ϩ cells and 1 from a Ly5.2 ϩ cell ( Figure 1D) . These results formally demonstrate that direct reprogramming of marrow hematopoietic cells is feasible given that transdifferentiation of HSCs to nonhematopoietic lineage cells is, if it ever occurs, an extremely rare event. 20 We named these iPSCs sHSC-iPS cells (sHSCiPSCs) specifically when established from BM HSPCs reconstituted from a single HSC.
Each sHSC-iPSC clone was demonstrated to retain proviral sequences of the 4 iPSC factors (supplemental Figure 2A) , without detectable transgene expression, probably resulting from gene silencing (supplemental Figure 2B) . In contrast, all sHSC-iPSCs were found to express each iPSC factor gene endogenously (supplemental Figure 2B) . All sHSC-iPSCs were shown to express the ES cell marker genes Nanog, ERas, Rex1, and Gdf3 (supplemental Figure 3A) . Nanog expression was also confirmed by immunostaining (supplemental Figure 3B ). Despite the low expression levels of Ecat1 and Zfp296, another set of ES cell marker genes, these sHSC-iPSCs were shown to For personal use only. on April 14, 2017. by guest www.bloodjournal.org From be competent in both teratoma formation (supplemental Figure 4) and contribution to chimeric mice ( Figure 1E ).
We next sought to confirm the reproducibility of direct reprogramming of primary BM HSPCs. Lin Ϫ Kit ϩ BM cells obtained from adult B6 mice were subjected to retrovirus-mediated reprogramming procedures ( Figure 1B) . From approximately 5 ϫ 10 5 HSPCs, we consistently obtained approximately 10 to 30 discrete colonies with typical ES cell-like appearances that stained for ALP (data not shown). Interestingly, iPSC clones established from primary BM HSPCs (pHPC-iPSCs) were shown to express ES cell marker genes more robustly than did sHSC-iPSCs ( Figures  2A, S3A) . Expression levels in endogenous iPSC factor genes were also more intense in pHPC-iPSCs (supplemental Figure 5B ) than in sHSC-iPSCs (supplemental Figure 2B) . This may support the idea that huge replicative stress imposed on a single HSC by hematopoietic reconstitution might restrict effective reprogramming of target cells, which are thought to be in senescent states. Confirmation of germline configuration in the immunoglobulin gene revealed the non-B-cell origin of pHPC-iPSCs ( Figure 2B ). pHPC-iPSCs had the potential for multilineage differentiation, as evidenced by the formation of teratomas, which contained various tissues representing all 3 germ layers ( Figure 2C ). We were also successful in generating pHPC-iPSCs that constitutively expressed green fluorescence protein from enhanced green fluorescent protein (EGFP)-transgenic mice 21 ( Figure 2D ). These iPSCs showed a high contribution to embryonic development when microinjected into blastocysts ( Figure 2E ).
Here we report generation of iPSCs from hematopoietic cells with unrearranged immunoreceptor genes by direct viral transfer of iPSC factors. The principle shown here ensures the feasibility of direct reprogramming of human hematopoietic cells, in conjunction with the recent report of iPSC generation from human blood. 8 The defined cellular origin of our iPSCs enables formal comparative studies using iPSC clones from various sources: One intriguing question is whether or not our iPSC clones differ from those generated from other tissues in respect to reprogramming efficiency, genomic stability, ability of tissue differentiation, and susceptibility to tumorigenesis. Another question is what types of cells in murine HSPCs are actually reprogrammed into iPSCs. At present, we have not yet succeeded in iPSC generation from highly purified HSCs. Considering the germline configuration of the immunoglobulin gene in our iPSC clones ( Figure 2B ) and the fact that the transduced cells rapidly acquired granulocytic/myeloid-lineage marker expression in our culture conditions (data not shown), myeloid progenitors are currently the plausible target cells of iPSC induction in our system. Studies to address all these issues are ongoing. using 293GPG cells; K.E. and H.E. supported experiments with their professional knowledge and experience; and M. Otsu and H.N. supervised the study.
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